Healthcare tech company Privia Health Group (NASDAQ:PRVA) will be reporting results this Thursday before the bell. Here’s what you need to know.
Privia Health beat analysts’ revenue expectations by 6.5% last quarter, reporting revenues of $480.1 million, up 15.6% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EPS estimates and sales volume in line with analysts’ estimates.
Is Privia Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Privia Health’s revenue to grow 11.3% year on year to $470 million, improving from the 2.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.20 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Privia Health has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 4.4% on average.
Looking at Privia Health’s peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Omnicell delivered year-on-year revenue growth of 5%, beating analysts’ expectations by 4.9%, and Hims & Hers Health reported revenues up 72.6%, falling short of estimates by 1.1%. Omnicell’s stock price was unchanged after the resultswhile Hims & Hers Health was down 12.5%.
Read our full analysis of Omnicell’s results here and Hims & Hers Health’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Privia Health is down 8.9% during the same time and is heading into earnings with an average analyst price target of $30.25 (compared to the current share price of $19.45).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.